首页> 外文期刊>Acta Pharmaceutica Sinica B >Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway
【24h】

Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway

机译:通过抑制缺口/ NF-κB和RAS / RAF / MEK / ERK信号通路,通过抑制NOTCH / NF-κB和RAS / RAF / ERK信号传导通路来协同抑制DOX抗性乳腺癌进展。

获取原文
       

摘要

Resistance to breast cancer (BCa) chemotherapy severely hampers the patient's prognosis. MicroRNAs provide a potential therapeutic prospect for BCa. In this study, the reversal function of microRNA34a (miR34a) on doxorubicin (Dox) resistance of BCa and the possible mechanism was investigated. We found that the relative level of miR34a was significantly decreased in Dox-resistant breast cancer cell MCF-7 (MCF-7/A) compared with Dox-sensitive MCF-7?cells. Transfection with miR34a significantly suppressed the invasion, migration, adhesion of MCF-7/A cells without inhibiting their growth obviously. The combination of miR34a and Dox could significantly inhibit the proliferation, migration, invasion and induce the apoptosis of MCF-7/A cells. The synergistic effect of this combination on resistant MCF-7/A cells has no obvious relation with the expressions of classical drug-resistant proteins P-GP, MRP and GST- π , while closely related with the down-regulation on TOP2A and BCRP. Moreover, we found both protein and mRNA expression of Snail were significantly up-regulated in MCF-7/A cells in comparison with MCF-7?cells. Transfection with small interfering RNA (siRNA) of Snail could inhibit the invasion, migration and adhesion of drug-resistant MCF-7/A cells, while high-expression of Snail could remarkably promote the invasion, migration and adhesion of MCF-7?cells, which might be related with regulation of N-cadherin and E-cadherin. Transfection with miR34a in MCF-7/A cells induced a decrease of Snail expression. The potential binding sites of miR34a with 3′ UTR of Snail were predicted by miRDB target prediction software, which was confirmed by luciferase reporter gene method. Results showed that the relative activity of luciferase was reduced in MCF-7/A cells after co-transfection of miR34a and wild type (wt)-Snail, while did not change by co-transfection with miR34a and 3′ UTR mutant type (mut) Snail. Combination of miR34a and Dox induced a stronger decrease of Snail in MCF-7/A cells in comparison to miR34a or Dox treatment alone. What’ more, for the first time, we also found miR34a combined with Dox could obviously inhibit the expression of Snail through suppressing Notch/NF- κ B and RAS/RAF/MEK/ERK pathway in MCF-7/A cells. In?vivo study indicated that combination of miR34a and Dox significantly slowed down tumor growth in MCF-7/A nude mouse xenograft model compared with Dox alone, which was manifested by the down-regulation of Snail and pro-apoptosis effect in tumor xenografts. These results together underline the relevance of miR34a-driven regulation of Snail in drug resistance and co-administration of miR34a and Dox may produce an effective therapy outcome in the future in clinic.
机译:抗乳腺癌(BCA)化疗严重妨碍患者的预后。 MicroRNA为BCA提供潜在的治疗前景。在该研究中,研究了MicroRNA34a(miR34a)对BCA的多柔比星(DOX)电阻的逆转功能及可能的机制。与DOX敏感MCF-7?细胞相比,我们发现在DOX抗性乳腺癌细胞MCF-7(MCF-7 / A)中,MIR34a的相对水平显着降低。用miR34a转染显着抑制了MCF-7 /细胞的侵袭,迁移,粘附,而不明显抑制其生长。 miR34a和dox的组合可以显着抑制增殖,迁移,侵袭和诱导MCF-7 /细胞的凋亡。这种组合对抗性MCF-7 /细胞的协同效应与古典耐药蛋白P-GP,MRP和GST-π的表达没有明显的关系,同时与TOP2A和BCRP的下调密切相关。此外,与MCF-7?细胞相比,我们发现蜗牛的蛋白质和mRNA表达在MCF-7 / A细胞中显着上调。用蜗牛的小干扰RNA(siRNA)转染可能抑制耐药MCF-7 /细胞的侵袭,迁移和粘附,而蜗牛的高表达可能会显着促进MCF-7?细胞的侵袭,迁移和粘附性,这可能与N-cadherin和E-cadherin的调节有关。用MIR34a在MCF-7 /细胞中转染诱导蜗牛表达的减少。 MiR34a的潜在结合位点与蜗牛的3'UTR的肌肌预测软件预测,由荧光素酶报告基因方法证实。结果表明,在MiR34a和野生型(wt)的共转染后,MCF-7 /细胞中荧光素酶的相对活性降低,同时不通过与miR34a和3'utr突变体类型的共转染(mut )蜗牛。与单独的miR34a或dox治疗相比,MiR34a和Dox的组合诱导MCF-7 /细胞中的蜗牛减少。什么是,首次,我们也发现MiR34a结合Dox可以通过抑制MCF-7 /细胞中的凹口/ NF-κB和RAS / RAF / MEK / ERK途径来抑制蜗牛的表达。在α体内研究表明,与单独的DOX相比,MiR34a和Dox的组合在MCF-7 /裸鼠异种移植模型中显着减缓了肿瘤生长,其表现为肿瘤异种移植物中的蜗牛和促凋亡作用的下调。这些结果将MiR34A驱动的蜗牛调节在耐药性和MiR34a和Dox的共同施用中的相关性可以在临床中产生有效的治疗结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号